Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses
批准号:
9418347
负责人:
Paul A. Goepfert
金额:
$79.0万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-06-01 至 2022-05-31
关键词:
AcuteAddressAffectAllelesAmino Acid SubstitutionAmino AcidsAntiviral AgentsBiologicalBiological AssayBiological PreservationCD4 Positive T LymphocytesCell physiologyCellsClinicalClinical Course of DiseaseClinical MarkersComputer AnalysisCytometryDiseaseDisease ProgressionEpitopesEvolutionFrequenciesFutureGoalsHIVHIV InfectionsHIV vaccineHIV-1HIV-1 vaccineImmuneImmune responseImmunityImmunologic MonitoringImpairmentIndividualInfectionLinkMapsMeasuresMediatingMutationOutcomePathogenesisPatientsPeruvianPhenotypePopulationPreventionPreventive vaccineRegimenRoleTechniquesTestingVaccine DesignVaccinesVariantViralViral Load resultVirusadaptive immunityantiretroviral therapybasecohortdesignefficacy studygenetic profilingimmune activationimmunogenicimmunogenicityin vivonovelpressureprogression markerresponsetranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Due to their multiple roles in adaptive immunity, induction of robust CD4 T cells (CD4) is a desirable goal for any
preventative vaccine. Since these cells are the primary targets of HIV infection, their antiviral role in HIV immunity
has been relatively understudied. We have shown immune pressure by effector CD4 drive viral escape, but the
role of these cells and the implications of CD4 immune escape in HIV pathogenesis is unclear. We linked amino
acid changes (termed mutations or adaptations) to specific HLA-II alleles and defined adapted epitopes (AE),
where single amino acid substitutions reflect CD4-mediated immune pressure. The complementary non-
adapted epitope (NAE) shows no evidence of mutation when assessed at a population level. These adaptations
can accrue in a viral population, and the extent of adaptation in a new host is dependent upon their respective
HLA-II alleles. We previously confirmed that AE represent immune escape from CD4 T cells and found the
magnitude and function of AE-specific CD4 T cell responses were diminished, but the impact of CD4-restricted
epitope adaptations on CD4 T cell immunity is unknown. Our overall hypothesis is that CD4 T cells targeting-
NAE have a distinct functional phenotype able to control HIV replication, which is compromised by viral
adaptation to these responses.
Since initiating ART immediately after infection preserves CD4 T cells, this application will address whether early
ART promotes better viral control by allowing CD4 T cells to target NAE, responses known to be beneficial as
compared to AE. We will test this hypothesis using a unique cohort of clade B acutely infected Peruvians where
patients receive antiretroviral therapy (ART) either immediately or 6 months post infection. In specific aim 1, we
will determine the biologic relevance of HIV adaptation to CD4 T cells. To do so, we will determine the ability of
CD4 T cells to inhibit virus that is fully adapted or non-adapted to these responses. We will also assess the
extent to which HLA-II adaptation in the transmitted virus influences clinical disease course in that individual. In
specific aim 2, we will decipher the functional differences (globally and at single cell level) that define an AE or
NAE specific CD4 T cell response and determine whether immediate ART optimizes CD4 T cells by targeting
NAE encoded in the infecting virus. In specific aim 3, we will determine the impact of CD4 T cell adaptation on
vaccine immunogenicity and efficacy. We will evaluate the function of CD4 T cells in vaccinees as it relates to
NAE and AE responses. We will also determine whether adaptation of the vaccine insert influences rates of HIV
infection. In summary, CD4 T cell mediated escape implies an in-vivo survival advantage of HIV adaptation and
suggests CD4 T cells are indeed important to immune control of HIV. Elucidating the mechanisms of CD4 T cell
immunity in HIV infection and the relevance of HIV escape to these responses will benefit the design of future
HIV-1 preventative vaccine strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The impact of HIV adaptation to CD8 T cells on infection and viral control
-
批准号:10245517
-
项目类别:
-
资助金额:$66.21万
-
财政年份:2020
-
负责人:Paul A. Goepfert
-
依托单位:
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses
-
批准号:10186453
-
项目类别:
-
资助金额:$62.81万
-
财政年份:2017
-
负责人:Paul A. Goepfert
-
依托单位:
A Rational Approach for HIV Vaccine T Cell Epitope Selection
-
批准号:8797988
-
项目类别:
-
资助金额:$48.77万
-
财政年份:2014
-
负责人:Paul A. Goepfert
-
依托单位:
A Rational Approach for HIV Vaccine T Cell Epitope Selection
-
批准号:9087090
-
项目类别:
-
资助金额:$46.38万
-
财政年份:2014
-
负责人:Paul A. Goepfert
-
依托单位:
A Rational Approach for HIV Vaccine T Cell Epitope Selection
-
批准号:8892071
-
项目类别:
-
资助金额:$46.26万
-
财政年份:2014
-
负责人:Paul A. Goepfert
-
依托单位:
A Rational Approach for HIV Vaccine T Cell Epitope Selection
-
批准号:9302653
-
项目类别:
-
资助金额:$46.38万
-
财政年份:2014
-
负责人:Paul A. Goepfert
-
依托单位:
Analysis of Variant Epitope Specific CD8 T-Cells to Optimize HIV Vaccine Design
-
批准号:8546018
-
项目类别:
-
资助金额:$63.62万
-
财政年份:2012
-
负责人:Paul A. Goepfert
-
依托单位:
CTL and HIV Polymorphisms in Heterosexual Transmission
-
批准号:8069728
-
项目类别:
-
资助金额:$25.06万
-
财政年份:2010
-
负责人:Paul A. Goepfert
-
依托单位:
HIV-1 Cryptic Epitopes: Implications for Vaccine Design
-
批准号:8131729
-
项目类别:
-
资助金额:$50.19万
-
财政年份:2009
-
负责人:Paul A. Goepfert
-
依托单位:
Clinical
-
批准号:7685017
-
项目类别:
-
资助金额:$38.66万
-
财政年份:2009
-
负责人:Paul A. Goepfert
-
依托单位:
HIV-1 Cryptic Epitopes: Implications for Vaccine Design
-
批准号:7928730
-
项目类别:
-
资助金额:$51.71万
-
财政年份:2009
-
负责人:Paul A. Goepfert
-
依托单位:
HIV-1 Cryptic Epitopes: Implications for Vaccine Design
-
批准号:8319514
-
项目类别:
-
资助金额:$50.04万
-
财政年份:2009
-
负责人:Paul A. Goepfert
-
依托单位:
HIV-1 Cryptic Epitopes: Implications for Vaccine Design
-
批准号:8526357
-
项目类别:
-
资助金额:$45.11万
-
财政年份:2009
-
负责人:Paul A. Goepfert
-
依托单位:
HIV-1 Cryptic Epitopes: Implications for Vaccine Design
-
批准号:7760837
-
项目类别:
-
资助金额:$52.28万
-
财政年份:2009
-
负责人:Paul A. Goepfert
-
依托单位:
Clinical
-
批准号:7697006
-
项目类别:
-
资助金额:$15.45万
-
财政年份:2008
-
负责人:Paul A. Goepfert
-
依托单位:
A-Z Clinical Trials Unit
-
批准号:10528462
-
项目类别:
-
资助金额:$186.27万
-
财政年份:2007
-
负责人:Paul A. Goepfert
-
依托单位:
HIV-1 Suppression by MHC class I restricted CD8 T Cells
-
批准号:7282233
-
项目类别:
-
资助金额:$21.75万
-
财政年份:2007
-
负责人:Paul A. Goepfert
-
依托单位:
HIV-1 Suppression by MHC class I restricted CD8 T Cells
-
批准号:7416726
-
项目类别:
-
资助金额:$17.78万
-
财政年份:2007
-
负责人:Paul A. Goepfert
-
依托单位:
A-Z Clinical Trials Unit
-
批准号:10305654
-
项目类别:
-
资助金额:$189.98万
-
财政年份:2007
-
负责人:Paul A. Goepfert
-
依托单位:
CTL and HIV Polymorphisms in Heterosexual Transmission
-
批准号:8449667
-
项目类别:
-
资助金额:$134.07万
-
财政年份:2005
-
负责人:Paul A. Goepfert
-
依托单位:
海外基金